- Summits
- Sponsorship
- Retreats
- Media Opportunities
- News
- About
In a milestone moment for the growing intersection of space technology and life sciences, Luxembourg-based Exobiosphere has secured a $1 million investment after winning the season finale of Meet the Drapers, the globally broadcast venture capital competition hosted by renowned investor Tim Draper. The show’s format awards its winner $1 million investment, placing Exobiosphere among a select group of globally recognised startups.
Selected from thousands of applicants worldwide, Exobiosphere progressed through three highly competitive rounds before emerging as the winner in the finale aired on March 31. For a company working on Orbital High-Throughput System, the victory represents both financial backing and a strong vote of confidence in the future of space-enabled biomedical research.
At the heart of Exobiosphere’s work is a bold premise: some of the most important breakthroughs in drug discovery may not happen on Earth.
The company, widely recognised as the world’s first space-based contract research organisation focused on drug discovery, is developing its proprietary Orbital High-Throughput Screening (OHTS) platform, designed to enable pharmaceutical and biotech partners to run automated biological experiments in microgravity. By taking disease modelling and compound screening into space, the platform aims to unlock cellular responses and therapeutic insights that are difficult, if not impossible, to reproduce in conventional Earth-based laboratories.
“This investment from Tim Draper and the Meet the Drapers platform is a tremendous validation of what we’re building at Exobiosphere,” said Kyle Acierno, CEO of Exobiosphere. “Tim Draper has a track record of recognising transformative ideas before they become mainstream, and we’re honoured that he sees the potential in what we’re building.”
That potential lies in the unique biological effects of microgravity.
Traditional in vitro disease research often struggles to fully capture the complexity of how diseases evolve inside the human body. In microgravity, however, cells can grow in more natural three-dimensional structures, allowing researchers to build models that more closely resemble physiological conditions.
This is particularly significant for complex and age-related diseases. In space, biological ageing processes and neurodegenerative conditions such as Alzheimer’s and Parkinson’s can progress at an accelerated rate, enabling researchers to observe years of disease development in a dramatically shorter timeframe.
Exobiosphere describes this as turning space into a time-accelerated laboratory for medicine.
In practical terms, the company’s OHTS platform is built to conduct more than 2,000 automated experiments per mission, bringing scale and standardisation to a research environment that has historically been limited by access and operational complexity.
That scalability is what could make space-based biology commercially relevant for the pharmaceutical sector.
As one of the judges on the show, Rob Solomon, noted: “The hundred-times improvement is remarkable. But what really stood out to me is the transition of cells into 3D—I didn’t know that was possible. That opens up incredible opportunities to understand and study them at a much deeper level. It’s something that just makes a lot of sense.”
Another judge, Adam Draper, commented: “Pharma is already trying to run experiments in space—that’s real. But it’s been extremely limited because you actually have to go up to the ISS. Even basic processes become complicated—things just float away. It sounds almost absurd, but that’s the reality scientists deal with. What we’re really trying to do is move toward digitisation. To get there, we need data—because without data, you can’t digitise any of this.”
The timing is notable. Interest in orbital research infrastructure is increasing as commercial space stations move closer to deployment. Exobiosphere is already positioned within that next phase, having been confirmed as an official payload partner for Vast’s Haven-1, the world’s first commercial crewed space station, where installation of its OHTS system is scheduled for 2027.
The Meet the Drapers win adds to what has already been a strong period of momentum for the company.
Over the past year, Exobiosphere has continued to strengthen its position at the convergence of biotech and spacetech. Recent milestones include winning Boryung’s Human in Space Challenge, securing the Startup World Cup Luxembourg title, and landing collaborations with leading research institutions, including Cedars-Sinai and the University of Notre Dame.
The company also recently joined the Cedars-Sinai Accelerator+, backed by a $1.4 million strategic investment, further supporting the development of its orbital screening technology.
Earlier funding milestones include a €2 million seed round led by Expansion Ventures, with participation from Expon Capital and Space Data Inc., reinforcing investor appetite for technologies that sit at the edge of healthcare innovation and space infrastructure.
Founded in Luxembourg, with additional offices in Los Angeles and Houston, Exobiosphere is steadily establishing itself as a first mover in a category that is only beginning to take shape.
Its latest win suggests that investors increasingly see orbital biology not as a futuristic concept, but as a credible platform for accelerating therapeutic discovery here on Earth.
As breakthroughs across medtech, biotech, AI, and frontier healthcare technologies continue to gain momentum, the conversations shaping what comes next will take centre stage at MedTech World North America 2026 | West Palm Beach.
If you are looking to be part of this milestone flagship event, you can engage in ways that align with your goals:
From startups and investors to healthcare leaders, researchers, and industry decision-makers, the event brings together the people and ideas driving progress across the global healthcare ecosystem.
